Targeted drug duo shows promise in halting tough pancreatic cancer
Disease control
Completed
This study tested a combination of two oral drugs, vemurafenib and sorafenib, in 10 patients with advanced pancreatic cancer that had a specific genetic change (KRAS mutation) and had stopped responding to standard chemotherapy. The main goal was to see if the drug combo could co…
Phase: PHASE2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Apr 02, 2026 07:42 UTC